Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 19/20 | 1.00 |
| ▸ | DRD2 | P14416 | 15/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 17/20 | 0.68 |
| ▸ | CHRM4 | P08173 | 17/20 | 0.68 |
| ▸ | CHRM5 | P08912 | 17/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 17/20 | 0.68 |
| ▸ | DRD4 | P21917 | 13/20 | 0.68 |
| ▸ | DRD3 | P35462 | 13/20 | 0.68 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577992 | 0.83 | DRD2 (0.70) | CHRM1DRD2KCNH2CHRM2CHRM4 | |
| SCHEMBL6580566 | 0.81 | DRD2 (0.68) | CHRM1DRD2KCNH2CHRM2CHRM4 | |
| SCHEMBL6580439 | 0.78 | DRD2 (0.64) | CHRM1DRD2KCNH2CHRM2CHRM4 | |
| SCHEMBL6580501 | 0.78 | DRD2 (0.68) | CHRM1DRD2KCNH2CHRM2CHRM4 | |
| SCHEMBL6580634 | 0.77 | DRD2 (0.62) | CHRM1DRD2KCNH2CHRM2CHRM4 | |
| SCHEMBL6578149 | 0.76 | GRIN1 (0.66) | CHRM1DRD2KCNH2CHRM2CHRM4 | |
| SCHEMBL5396144 | 0.75 | HTR1A (0.66) | CHRM1DRD2KCNH2CHRM2CHRM4 | |
| SCHEMBL5380399 | 0.75 | DRD2 (0.60) | CHRM1DRD2KCNH2CHRM2CHRM4 | |
| SCHEMBL4235731 | 0.75 | CHRM1 (0.77) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| SCHEMBL5388161 | 0.73 | DRD2 (0.58) | CHRM1DRD2KCNH2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299380-B1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2004-06-09 | — | — | EP | disclosed |
| US-20030232822-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DE) | 2003-12-18 | — | — | US | disclosed |
| EP-1299380-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002000645-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232822-A1 | Indole derivatives useful for the treatment of CNS disorders | CHRM1, TPH1, CHRNA6 | CHRM1 1/4885DRD2 162/4885KCNH2 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.